173 related articles for article (PubMed ID: 38136668)
21. Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues.
Zheng Y; Zhang J; Xu ZZ; Sheng JM; Zhang XC; Wang HH; Teng XD; Liu XJ; Cao J; Teng LS
J Zhejiang Univ Sci B; 2010 Feb; 11(2):144-50. PubMed ID: 20104649
[TBL] [Abstract][Full Text] [Related]
22. Expression Significance of Estrogen Receptor ER-α36 in Breast Cancer Treated by Chemotherapy: A Meta-Analysis.
He E; Xia X; Quan H; Leng P
Mol Biotechnol; 2024 May; 66(5):991-999. PubMed ID: 38270756
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
Wang ZY; Yin L
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
[TBL] [Abstract][Full Text] [Related]
24. A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells.
Kang L; Guo Y; Zhang X; Meng J; Wang ZY
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):262-8. PubMed ID: 21907803
[TBL] [Abstract][Full Text] [Related]
25. Icariin, a phytoestrogen, exerts rapid estrogenic actions through crosstalk of estrogen receptors in osteoblasts.
Wong KY; Kong TH; Poon CC; Yu W; Zhou L; Wong MS
Phytother Res; 2023 Oct; 37(10):4706-4721. PubMed ID: 37421324
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor variant ER-α36 facilitates estrogen signaling via EGFR in glioblastoma.
Qu C; Wang C; Li H; Li Y; Han C; Tao X; Guan X; Zhang Y; Chen M; Liu J; Zou W
Cell Biol Int; 2022 Nov; 46(11):1759-1774. PubMed ID: 35930599
[TBL] [Abstract][Full Text] [Related]
27. Predictive and prognostic value of ER-α36 expression in breast cancer patients treated with chemotherapy.
Yu L; Ke W; Wang Y; Ding W; Wang B; Huang S; Chen J; Wang X; Wang Z; Shen P
Steroids; 2014 Jun; 84():11-6. PubMed ID: 24632025
[TBL] [Abstract][Full Text] [Related]
28. ER-α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance.
Teymourzadeh A; Mansouri S; Farahmand L; Hosseinzade A; Majidzadeh-A K
Clin Breast Cancer; 2017 Oct; 17(6):403-407. PubMed ID: 28433540
[TBL] [Abstract][Full Text] [Related]
29. Progress in the Understanding of Estrogen Receptor Alpha Signaling in Triple-Negative Breast Cancer: Reactivation of Silenced ER-α and Signaling through ER-α36.
Al-Kabariti AY; Abbas MA
Mol Cancer Res; 2023 Nov; 21(11):1123-1138. PubMed ID: 37462782
[TBL] [Abstract][Full Text] [Related]
30. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.
Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE
Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634
[TBL] [Abstract][Full Text] [Related]
31. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
33. Lower expression of ER-α36 is associated with the development of endometrial hyperplasia in PCOS patients.
Lin SL; Tu BB; Du XG; Yan LY; Qiao J
Histol Histopathol; 2013 Nov; 28(11):1491-8. PubMed ID: 23690166
[TBL] [Abstract][Full Text] [Related]
34. ER-α36: a novel biomarker and potential therapeutic target in breast cancer.
Su X; Xu X; Li G; Lin B; Cao J; Teng L
Onco Targets Ther; 2014; 7():1525-33. PubMed ID: 25210466
[TBL] [Abstract][Full Text] [Related]
35. The ER-α36/EGFR signaling loop promotes growth of hepatocellular carcinoma cells.
You H; Meng K; Wang ZY
Steroids; 2018 Jun; 134():78-87. PubMed ID: 29481815
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor variant ER-α36 promotes tamoxifen agonist activity in glioblastoma cells.
Qu C; Ma J; Zhang Y; Han C; Huang L; Shen L; Li H; Wang X; Liu J; Zou W
Cancer Sci; 2019 Jan; 110(1):221-234. PubMed ID: 30417588
[TBL] [Abstract][Full Text] [Related]
37. Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.
Yin L; Zhang XT; Bian XW; Guo YM; Wang ZY
PLoS One; 2014; 9(9):e107369. PubMed ID: 25203051
[TBL] [Abstract][Full Text] [Related]
38. ER-α36 Promotes the Malignant Progression of Cervical Cancer Mediated by Estrogen
Wang C; Zhang T; Wang K; Zhang S; Sun Q; Yang X
Front Oncol; 2021; 11():712849. PubMed ID: 34336701
[TBL] [Abstract][Full Text] [Related]
39. Estrogen receptor variant ER-α36 is involved in estrogen neuroprotection against oxidative toxicity.
Han S; Zhao B; Pan X; Song Z; Liu J; Gong Y; Wang M
Neuroscience; 2015 Dec; 310():224-41. PubMed ID: 26383254
[TBL] [Abstract][Full Text] [Related]
40. Role of ER-α36 in breast cancer by typical xenoestrogens.
Liu J; Xu Z; Ma X; Huang B; Pan X
Tumour Biol; 2015 Sep; 36(10):7355-64. PubMed ID: 26337277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
